Neuralink Approved for First Clinical Trial in Canada Using N1 Chip for ALS and SCI Patients

Nov 20, 2024, 07:51 PM

Neuralink has received approval from Health Canada to initiate recruitment for its first clinical trial in Canada, aimed at individuals with quadriplegia due to ALS or spinal cord injury (SCI). The trial will utilize Neuralink's N1 chip, which enables paralyzed individuals to control devices such as computers through brain-computer interface (BCI) technology. This advancement is expected to have a transformative impact on the lives of many. Interested participants can find more information and apply through Neuralink's Patient Registry.